Pacira BioSciences, Inc. (PCRX) research
Pacira BioSciences, Inc.- Sector
- Pharmaceuticals
- Last price
- $25.21
- As of
Pacira BioSciences, Inc. (PCRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
As of . Source: SEC EDGAR filings for PCRX. Method and limitations.
Share the PCRX intelligence card
See the full PCRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PCRX on one page. Preview it with sample data, then open it live with a free account.
Preview the PCRX dossierActive signals for PCRX
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +312% to PCRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1878% to PCRX (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 10.6%, EPS $0.73 vs $0.6603 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 53% of PCRX (2026Q1)
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 5.3% - EPS $0.7 vs $0.6649 estimate
FREE, NO ACCOUNT
Every signal on PCRX, as it fires
You are seeing 5 of 6 signals recorded on PCRX since 2026-06-02.
The five above landed across 4 days. The other 1 were recorded on those same days. 3 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PCRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 695127100 · 2026Q2 | $49.5M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 695127100 · 2026Q2 | $44M | 0.06% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 695127100 · 2026Q2 | $18.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 695127100 · 2026Q2 | $6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 695127100 · 2026Q2 | $4.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PCRX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PCRX against its peers
PCRX's operating margin of 2.6% ranks in the 47th percentile of 17 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | PCRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 726M USD | 407M USD | 69 | 20 |
| Gross margin | n/a | 56.3% | n/a | 6 |
| Operating margin | 2.6% | 8.5% | 47 | 17 |
| Net margin | 1.0% | -2.6% | 55 | 18 |
| Return on equity | 1.0% | -20.4% | 63 | 22 |
| P / E | 157.6x | 14.2x | 94 | 8 |
Peers (25): ANRO, ALMS, AMPH, ESPR, OMER, ACRS, PAHC, COLL, INVA, OCUL, ANIP, XERS, NUVB, TRVI, NKTR, BHC, GPCR, HRMY, AVIR, SUPN, BIOA, OGN, FULC, TARS, AMLX. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PCRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PCRXand get the insider, 13F, options, and confluence read in one view.